Faron Pharmaceuticals' (LON:FARN) Markku Jalkanen (CEO) pitches to investors at the Proactive One2One live virtual forum.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.
The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.